Clarithromycin — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Peptic Ulcer Disease / H. pylori

• Amoxicillin
• Omeprazole
• Amoxicillin 1,000 mg
• Clarithromycin 500 mg (triple therapy components)
• Omeprazole 20/40 mg

Other medications in Infections

• Colistin
• Dalbavancin
• Darunavir
• Dicloxacillin
• Dolutegravir
• Doripenem
• Efavirenz
• Emtricitabine

About Clarithromycin

Clarithromycin is a powerful antibiotic frequently prescribed to combat a range of bacterial infections. As part of the macrolide class, it's a vital tool in modern medicine. At TheDrugClub, we believe essential medications should be affordable and easy to access. Discover how our membership can bring you significant savings on clarithromycin and many other prescriptions.

Clarithromycin is a widely used antibiotic that belongs to the macrolide family. It's a versatile medication, prescribed by doctors to treat a variety of bacterial infections throughout the body. Common conditions it addresses include respiratory tract infections such as bronchitis, pneumonia, and sinusitis, as well as skin infections, ear infections, and even certain types of stomach ulcers caused by *H. pylori* bacteria. It's also used to prevent and treat disseminated Mycobacterium Avium Complex (MAC) infection in people with advanced HIV infection. It's crucial to remember that clarithromycin is effective only against bacterial infections and will not work for viral illnesses like the common cold or flu.

So, how does this antibiotic work its magic? Clarithromycin functions by targeting the bacteria's ability to produce essential proteins. Specifically, it binds to a specific part of the bacteria's ribosomes, which are the cellular machinery responsible for protein synthesis. By inhibiting this process, clarithromycin prevents the bacteria from growing, multiplying, and spreading, ultimately allowing your body's immune system to clear the infection. This action makes it a bacteriostatic antibiotic, meaning it stops bacterial growth, though at higher concentrations it can also be bactericidal, actively killing the bacteria.

For many, the cost of prescription medications can be a significant barrier to treatment. The typical out-of-pocket cost for a course of generic clarithromycin can vary widely depending on the dosage, quantity, and the pharmacy you choose, often ranging anywhere from $30 to over $100 without insurance. Even with insurance, co-pays can still add up, especially for those on high-deductible plans. The brand-name version, Biaxin, is considerably more expensive. These costs can force individuals to make difficult choices about their health, sometimes leading to

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Clarithromycin is approved for (FDA label)

Clarithromycin tablets are a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults ( 1.1 ) Acute Maxillary Sinusitis ( 1.2 ) Community-Acquired Pneumonia ( 1.3 ) Pharyngitis/Tonsillitis ( 1.4 ) Uncomplicated Skin and Skin Structure Infections ( 1.5 ) Acute Otitis Media in Pediatric Patients ( 1.6 ) Treatment and Prophylaxis of Disseminated Mycobacterial Infections ( 1.7 ) Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults ( 1.8 ) Limitations of Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.9 ) 1.1 Acute Bacterial Exacerbation of Chronic Bronchitis Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae [see Indications and Usage (1.9) ]. 1.2 Acute Maxillary Sinusitis Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Moraxella catarrhalis , or Streptococcus pneumoniae [see Indications and Usage (1.9) ]. 1.3 Community-Acquired Pneumonia Clarithromycin tablets are indicated [see Indications and Usage (1.9) ] for the treatment of mild to moderate infections caused by susceptible isolates due to: Haemophilus influenzae (in adults) Mycoplasma pneumoniae , Streptococcus pneumoniae , Chlamydophila pneumoniae (clarithromycin tablets [in adults and pediatric patients]) 1.4 Pharyngitis/Tonsillitis Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Streptococcus pyogenes as an alternative in individuals who cannot use first line therapy. 1.5 Uncomplicated Skin and Skin Structure Infections Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Staphylococcus aureus , or Streptococcus pyogenes . 1.6 Acute Otitis Media Clarithromycin tablets are indicated in pediatric patients for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Moraxella catarrhalis , or Streptococcus pneumoniae [see Clinical Studies (14.2) ] . 1.7 Treatment and Prophylaxis of Disseminated Mycobacterial Infections Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Mycobacterium avium or Mycobacterium intracellulare in patients with advanced HIV infection [see Clinical Studies (14.1) ] . 1.8 Helicobacter pylori Infection and Duodenal Ulcer Disease Clarithromycin tablets are given in combination with other drugs in adults as described below to eradicate H. pylori . The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence [see Clinical Studies (14.3) ] . Clarithromycin tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori . Clarithromycin tablets in combination with PRILOSEC (omeprazole) capsules are indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection.

Source: Read the full FDA label on DailyMed. Label effective date: June 24, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Clarithromycin (FDA label)

Clarithromycin tablets USP are available as: 500 mg: light yellow colored, oval shaped, biconvex film-coated tablets, with ‘D’ debossed on one side and ‘63’ on the other side. Tablets: 500 mg ( 3)

Source: FDA prescribing information (DailyMed). Set ID: 9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6. SPL document ID: 5501056f-14b9-a8b2-e063-6294a90ac6ea. Label effective date: June 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Clarithromycin (FDA label)

The following serious adverse reactions are described below and elsewhere in the labeling: • Acute Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] • QT Prolongation [see Warnings and Precautions (5.2) ] • Hepatotoxicity [see Warnings and Precautions (5.3) ] • Serious Adverse Reactions Due to Concomitant Use with Other Drugs [see Warnings and Precautions (5.4) ] • Clostridium difficile Associated Diarrhea [see Warnings and Precautions (5.6) ] • Exacerbation of Myasthenia Gravis [see Warnings and Precautions (5.8) ] Most frequent adverse reactions for both adult and pediatric populations in clinical trials: abdominal pain, diarrhea, nausea, vomiting, dysgeusia ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Based on pooled data across all indications, the most frequent adverse reactions for both adult and pediatric populations observed in clinical trials are abdominal pain, diarrhea, nausea, vomiting and dysgeusia. Also reported were dyspepsia, liver function test abnormal, anaphylactic reaction, candidiasis, headache, insomnia, and rash. The subsequent subsections list the most common adverse reactions for prophylaxis and treatment of mycobacterial infections and duodenal ulcer associated with H. pylori infection.

Source: FDA prescribing information (DailyMed). Set ID: 9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6. SPL document ID: 5501056f-14b9-a8b2-e063-6294a90ac6ea. Label effective date: June 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Clarithromycin (FDA label)

Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1) ] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions (7) ] . There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets.

Source: FDA prescribing information (DailyMed). Set ID: 9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6. SPL document ID: 5501056f-14b9-a8b2-e063-6294a90ac6ea. Label effective date: June 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Clarithromycin (FDA label)

Severe Acute Hypersensitivity Reactions : Discontinue clarithromycin if occurs ( 5.1 ) QT Prolongation : Avoid clarithromycin in patients with known QT prolongation or receiving drugs known to prolong the QT interval, ventricular arrhythmia ( torsades de pointes ), hypokalemia /hypomagnesemia, significant bradycardia, or taking Class IA or III antiarrhythmics ( 5.2 ) Hepatotoxicity: Discontinue if signs and symptoms of hepatitis occur ( 5.3 ) Serious adverse reactions can occur due to drug interactions of clarithromycin with colchicine, some lipid-lowering agents, some calcium channel blockers, and other drugs ( 5.4 ) Risk of all-cause mortality one year or more after the end of treatment in patients with coronary artery disease.

Source: FDA prescribing information (DailyMed). Set ID: 9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6. SPL document ID: 5501056f-14b9-a8b2-e063-6294a90ac6ea. Label effective date: June 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Clarithromycin (FDA label)

Co-administration of clarithromycin is known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug. Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Adjust dosage when appropriate and monitor serum concentrations of drugs primarily metabolized by CYP3A closely in patients concurrently receiving clarithromycin.

Source: FDA prescribing information (DailyMed). Set ID: 9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6. SPL document ID: 5501056f-14b9-a8b2-e063-6294a90ac6ea. Label effective date: June 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.